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Persufflation (PSF; gaseous oxygen perfusion) is an organ preservation technique with a potential for use in donor
heart preservation. Improved heart preservation with PSF may improve outcomes by maintaining cardiac tissue
quality in the setting of longer cold ischemia times and possibly increasing the number of donor hearts available
for allotransplant. Published data suggest that PSF is able to extend the cold storage times for porcine hearts up to
14 hours without compromising viability and function, and has been shown to resuscitate porcine hearts following
donation after cardiac death. This review summarizes key published work on heart PSF, including prospective
implications and future directions for PSF in heart transplantation. We emphasize the potential impact of extending
preservation times and expanding donor selection criteria in heart allotransplant. Additionally, the key issues that
need to be addressed before PSF were to become a widely utilized preservation strategy prior to clinical heart
transplantation are summarized and discussed.
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Recent advances in organ preservation have enabled im-
proved donor organ quality even in the setting of pro-
longed cold ischemia time (CIT). For example, strong
evidence now exists and supports the use of hypother-
mic machine perfusion (HMP) during kidney preserva-
tion [1-5], and excellent results were recently attained in
the first human clinical trials using HMP during liver
preservation [6]. It is believed that the use of HMP can
extend allowable periods of CIT without reducing the
overall metabolic quality of the organ [5]. In the case of
kidney transplantation, the extended time window may
further simplify the logistics of organ transportation
from the procurement site to the transplant center, and
facilitate distribution of kidneys across United Network
of Organ Sharing (UNOS) regions. In the case of heart
transplantation (unlike kidney transplantation), extended
CIT would enable transplantation of many more hearts
since prolonged preservation times are detrimental for* Correspondence: kkpapas@email.arizona.edu
1Division of Transplantation, Department of Surgery, University of Minnesota,
Minneapolis, MN, USA
3Institute for Cellular Transplantation, Department of Surgery, University of
Arizona, 1656 E. Mabel Street, Room 121, Tucson, AZ 85724, USA
Full list of author information is available at the end of the article
© 2013 Suszynski et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orheart transplant as historical data suggest that poorer
outcomes follow >4-6 hours of CIT [7]. The short allo-
wable CIT poses significant logistical challenges and
constrains heart allocation to a relatively small geogra-
phic area compared to other organs. Delays often occur
at the procurement site following thoracotomy in lieu of
communication with the transplant center to allow for
preparation of the recipient for transplant, particularly
in the case of a difficult reoperative chest. Furthermore,
the current time constraints effectively preclude human
leukocyte antigen (HLA) matching, which may offer sig-
nificant advantages for long-term graft and patient sur-
vival [8]. The inability to extend cold storage time may
also limit successful organ placement. With prospective
heart transplant recipients filling waiting lists, some of
whom are not eligible for ventricular assist devices, the
need to increase the number of transplantable hearts is
pressing.
A key area of research lies in the optimization of oxy-
gen delivery during hypothermic preservation. It has
been shown that conventional static cold storage (SCS)
techniques are incapable of providing sufficient oxygen to
the core of a large (human-sized) organ, and can only oxy-
genate to a maximum approximate depth of a millimeteral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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solubility of cold preservation solutions by using perfluo-
rocarbons have proven largely ineffective, because these
methods still rely on oxygen delivery by passive diffusion
from the surface alone. Even HMP, which has been de-
signed to deliver cold preservation solutions into the
organ via the native vasculature, may fail at delivering ad-
equate oxygen to an organ during preservation, such as
when the perfusate is not saturated with oxygen at a
higher than atmospheric oxygen partial pressure [10]. It is
in this regard that persufflation (PSF) or gaseous oxygen
perfusion may provide additional advantages as compared
to either SCS or HMP. Although not a new concept, PSF
can be considered an emerging (or reemerging) technique
for organ preservation and deserves considerable attention
for a variety of compelling reasons, including the unique
capability to deliver oxygen gas or gas mixture directly
into an organ by using the native vasculature. Compared
with SCS and HMP, PSF may represent the best opportun-
ity to fully oxygenate a human-sized organ, such as the hu-
man donor heart prior to clinical transplant.
The earliest experimental uses of oxygen PSF involved
the heart, particularly as a preservation technique dur-
ing experimental cardiopulmonary bypass (CPB). These
initial studies demonstrated that gaseous oxygen can be
utilized by myocardial tissue during periods of ischemia
and that heart function can be restored following short-
term PSF. Between the late 1960s and 1990s, investiga-
tion of PSF for heart preservation had slowed. The
reasons for this are somewhat unclear, but perhaps the
utility of PSF with other organs (i.e., kidney, liver) gar-
nered more appeal during this interim. Recently, how-
ever, cardiac PSF has experienced rekindled interest. As
detailed in this review, several studies have been pub-
lished recently in which PSF was used in preservation
prior to experimental heart transplantation. Among the
more intriguing applications has been the use of PSF to
preserve hearts following donation after cardiac death
(DCD) and short periods of warm ischemia. A timeline
of the more significant work in cardiac PSF is shown in
Figure 1. The collective results over the years have, atFigure 1 Historical timeline of persufflation. Significant contributions tominimum, suggested that cardiac PSF is technically
feasible and has potential for preservation of heart
tissue.
Review
Early history of persufflation
PSF was accidently discovered in 1902 by Rudolf
Magnus while studying ex vivo blood perfusion of isolated
feline hearts [11]. In an experiment, a blood-containing
reservoir had unexpectedly emptied and compressed oxy-
gen gas, which was used to drive blood perfusion, was
pulled into the perfusion circuit and in through the coron-
ary vasculature. Magnus observed that the heart conti-
nued to contract for several minutes while being perfused
(or persufflated) with oxygen gas instead of blood.
These earliest observations gave way to a series of ad-
ditional experiments performed by Magnus [11]. Not
until the mid-1950s was PSF studied more extensively
by a group at McGill University in Montreal [12,13]. In
1954, Bunzl et al. compared the benefits of PSF versus
liquid perfusion in a frog spinal reflex model, showing
that peripheral nerve reflexes and muscle contractions
could be preserved for up to 6–8 hours with PSF [12].
At that time, the authors observed a lack of edema for-
mation and improved oxygenation with PSF. In 1958,
Burns et al. showed that rabbit heart function could be
preserved for 3 hours using PSF [13]. This early work
prompted others to pursue cardiac PSF.
Early experiences in cardiac persufflation
In 1959, Sabiston et al. explored the use of PSF in con-
junction with CPB, a technique that was new to cardiac
surgery during that era [14]. In a first set of experiments,
the authors showed that canine hearts would continue
to beat for an average duration of 5 hours (2.5-8 hours,
range) at 37°C using continuous ex vivo anterograde PSF
(A-PSF) with humidified gaseous carbogen (95% O2, 5%
CO2). They observed sustained cardiac contractility du-
ring the first 2–3 hours of PSF, with gradual weakening
over time. In a second set of experiments, the authors
performed in situ A-PSF for 25–30 minutes after whichthe development of persufflation as a method of heart preservation.
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normal restoration of hemodynamic function in most
animals, with several animals maintaining a heartbeat
for 48 hours. The key conclusions of this study were that
1) the heart is able use oxygen gas via PSF during periods
of ischemia and 2) that normal hemodynamic para-
meters and coronary blood flow can be reestablished
after PSF.
In 1960, Talbert et al. introduced the concept of retro-
grade PSF (R-PSF) [15]. At the time, retrograde perfu-
sion of oxygenated blood via the coronary sinus was
used to maintain a heartbeat and protect the heart from
ischemia for short periods of time during open aortic
valve procedures [16,17]. In their studies, R-PSF via the
coronary sinus was able to maintain a visible heartbeat
for an average duration of 3.5 hours (2–4 hours, range).
If the anterior cardiac veins were cannulated in addition
to the coronary sinus, R-PSF was even more effective; a
visible beat was maintained for an average duration of
5.5 hours (Figure 2). The authors also compared R-PSF
with A-PSF and determined that the heartbeat was vis-
ibly weaker and sustained for a shorter period of time
using the retrograde approach, indicating that A-PSF
may be the best-suited approach for heart preservation.
In 1966, Camishion et al. published an article that
took Talberts’ concept of R-PSF and applied it during
CPB [18]. Despite the earlier work displaying the super-
iority of A-PSF, there was a clear advantage to R-PSF
within the context of CPB: R-PSF would not obstruct
the surgical view over the aortic valve (because it did
not involve cannulation of the coronary arteries). ToFigure 2 Cardiac anatomy relevant to persufflation. Sketch illustrating
development of persufflation; Anterograde persufflation has been performe
retrograde persufflation has been performed by cannulation of coronary sinaddress the question of whether R-PSF could preserve a
heart during CPB, Talberts’ previous work on in situ
R-PSF was basically repeated [15]. In a first experiment
they found that R-PSF with oxygen gas maintained sinus
rhythm in all canine hearts (n=10) for >30 minutes, and
that R-PSF with nitrogen gas abolished sinus rhythm at
≤5 minutes. In a second experiment, 83% of canine or
porcine hearts maintained sinus rhythm for one hour of
R-PSF during CPB. Following removal of CPB, 73%
remained in sinus rhythm. In addition to establishing
the utility of R-PSF with CPB, the authors cited no
evidence of air embolization in the brain or viscera of
any experimental animal. They also commented on the
difference between gas embolization and free gas flow
(which characterizes PSF), one that is not yet fully appre-
ciated by the clinical community and will need to be fur-
ther validated by scientific investigation. Interestingly,
the authors also speculated on the possible use of PSF
for donor heart preservation prior to cardiac transplan-
tation, nearly 2 years before the first successful human
heart transplant [19]. Several other studies were conduc-
ted in the late 1960s, including Gabel et al. (1966) [20]
and Lochner et al. (1968) [21] publishing on the metabo-
lism and function of rat, feline and guinea pig hearts.
Recent experiences in cardiac persufflation
During the next few decades (1970s-1990s), the use of
PSF with kidney and liver became the focus of study in
the field. The term ‘persufflation’ officially replaced ‘ga-
seous oxygen perfusion’ in 1971 [22]. Not until the late
1990s, however, was interest in cardiac PSF rekindled,the cardiac anatomy that has been historically relevant to the
d via the aorta or direct cannulation of coronary ostia, whereas
us with or without cannulation of the anterior cardiac veins.
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tion of PSF in other organs.
In 1998, Kuhn-Regnier et al. published a study ex-
ploring the use of A-PSF prior to orthotopic porcine
heart allotransplantation [23], a related study to the one
published by Fischer et al. that same year [24]. The
mean preservation time in this study was 14.5 hours.
They reported that persufflated hearts exhibited a car-
diac stroke work capacity that was similar when com-
paring pre-transplant versus post-transplant (which was
also post-PSF and post-CPB) function, whereas that was
not the case in organs preserved by SCS due to severe
arrhythmia and ventricular dyskinesia experienced post-
transplant. Furthermore, cardiac output (CO) in per-
sufflated hearts was significantly higher than in hearts
preserved by SCS alone. Their data indicated that A-PSF
permitted improved recovery of post-transplant cardiac
function when compared with SCS. They also noted less
myocardial edema with A-PSF versus SCS, which is im-
portant since tissue edema has been shown to significantly
impair cardiac function [25]. In 2000, Kuhn-Regnier et al.
performed another study in which they compared the
metabolic quality and post-transplant function of hearts
preserved by A-PSF versus SCS, and showed that both
were significantly improved in transplanted hearts follo-
wing A-PSF [26].
Up to this point in history, most studies of heart PSF
involved experimental procedures with hearts experien-
cing no “down-time” or conventional warm ischemia as
seen with DCD. The possibility of resuscitating DCD
hearts as a way to make more donor hearts available
for transplant became an intriguing concept. In 2003,
Yotsumoto et al. studied the effect of 3 hours of A-PSF
on post-transplant cardiac function following a mean
warm ischemia time (WIT) of 16.7 minutes in a porcine
(orthotopic) allotransplant model [27]. They discovered
that SCS hearts following zero WIT and persufflated
hearts following the prescribed WIT could be weaned
from CPB within 2 hours of transplantation, whereas the
SCS hearts following the prescribed WIT exhibited sig-
nificantly worse function and could not be weaned. At
1-hour of reperfusion, troponin T levels were signifi-
cantly higher in hearts preserved by SCS following the
prescribed WIT, versus either SCS following zero WIT
or A-PSF following the prescribed WIT. At the end of a
3-hour reperfusion period, all parameters of cardiac
function (including CO, left ventricular contractility, and
relaxation velocity) were significantly higher in hearts
preserved by A-PSF as compared to SCS. Their studies
indicated that A-PSF of a heart following DCD may en-
able preservation comparable to SCS of a heart following
conventional donation after brain death (with no WIT).
A major concern of the transplant field has been the
risk of endothelial damage imposed by PSF due to theintroduction of pressured gas through the coronary vascu-
lature. To address these concerns, studies were performed
and have shown that the coronary arteries of porcine
hearts following 3 hours of oxygen gas A-PSF exhibit
normal endothelial function post-transplant [28-30]. Addi-
tionally, hearts transplanted following 14 hours of A-PSF
showed no topographic signs of endothelial damage, as
assessed by scanning electron microscopy [29]. Fischer re-
cently published a book chapter in which the technical as-
pects of cardiac PSF are summarized [31] – including an
important discussion regarding the development of an
aortic valve guard to prevent gas efflux into the left
ventricle during A-PSF via the coronaries. Table 1 sum-
marizes the published work on heart PSF presented
in this review.
It is unclear why PSF has not been pursued with more
vigor. It may be that a stigma accompanies the concept
of introducing gas into the vasculature and, conse-
quently, has made clinicians skeptical of the potential
utility of PSF. There have been clinical trials in liver and
kidney transplantation using PSF as a method of organ
preservation, however these have been limited [32,33].
Perhaps concern for endothelial damage via desiccation
is another limiting factor – though gases can be humidi-
fied and, as mentioned previously, many studies have
shown that the endothelium does not appear disrupted
and remains functional [28,30] even following long-term
(14 hours) preservation by PSF and 7 days after hetero-
topic transplant [29]. Another possibility is that the lo-
gistics and safety concerns of transporting pressurized
oxygen gas are major deterrents, especially during air
travel, which is quite common and often necessary with
donor heart allocation and transplant. However, recent
technological advancements in developing portable de-
vices that are able to generate in situ oxygen from water
(via the use of electrochemical cells) have provided a
method to obviate the issue of having to use pressurized
gas cylinders. These devices have been used to generate
breathable oxygen for occupants of deployed submarines
and for patients with chronic pulmonary disease requiring
home oxygen therapy, and have been modified for use in
organ preservation (Giner Inc., Newton, MA) [34,35]. The
devices are small, easily transportable and also safe to use
in air travel. These technologies could enable PSF to be-
come more widely used as a preservation method for
organ transplantation. The increasing use of DCD organs
for transplantation has unmasked a clear need for further
advancement in organ preservation, an area of research
that has been stagnant in recent years. This technology
may prove to be a catalyst for such an advancement.
Future implications and directions
Though the field of clinical transplantation has made
considerable progress over the past half-century, an
Table 1 Summary of studies on heart persufflation












1902 Magnus R [11] A - ≤ 1.15 Cat - O2, H2, CO2 24-28 Cardiac activity during PSF
1958 Burns et al. [13] A - > 3 Rabbit - Carbogenb,
N2
37 Cardiac activity during PSF
1959 Sabiston et al. [14] A - < 8 Dog - Carbogenb,
N2
37 Cardiac activity during PSF
and after reperfusion
1960 Talbert et al. [15] R - 2-7 Dog - Carbogenb 37 Cardiac activity during PSF
and reperfusion
1966 Camishion et al.
[18]
R - < 7 Dog, Pig - O2, N2 38 Cardiac activity during PSF
1966 Gabel et al. [20] A - 10 Cat - Carbogenb 40 Cardiac activity and metabolic
profile during PSF
1968 Lochner et al. [21] A - < 1.5 Guinea pig,
Rat
- Carbogenb 4-37 Cardiac activity, WOOCR and
metabolic profile during PSF
2001 Fischer J [28] A 16 3.3 Pig (DCD) - O2 0-1 Coronary endothelial function




A - 14.5 Pig 3 hours O2 0-1 Cardiac function and metabolic
profile post-allotransplant
(orthotopic)















A - 14 Pig 7 days O2 0-1 Endothelial and myocardial
cell function post-allotransplant
(heterotopic)
Superscripts: aEither anterograde via the coronary arteries (denoted by ‘A’) or retrograde via the coronary sinus and possibly anterior cardiac veins (denoted by ‘R’);
bCarbogen is defined as a gas mixture composed of 95% oxygen and 5% CO2. Abbreviations: DCD, donation after cardiac death; PSF, persufflation; WOOCR, whole
organ oxygen consumption rate.
Suszynski et al. Journal of Cardiothoracic Surgery 2013, 8:105 Page 5 of 7
http://www.cardiothoracicsurgery.org/content/8/1/105indisputable and persistent problem has been the donor
organ shortage. Expansion of organ acceptance criteria,
DCD, living donation, paired donor exchanges, and im-
proving preservation methodology have all been strategies
employed to increase the quantity of organs available for
transplant [36-42]. Unfortunately, many of these strategies
are not applicable in heart transplantation for obvious rea-
sons, and suggest that improved organ preservation may
be of particular importance in the case of the heart. It is
conceivable that improved preservation techniques could
lengthen the allowable CIT, which would provide some re-
lief to the demanding logistical provisions that are needed
during the allocation and transport of a donor heart. A
substantial lengthening of the allowable CIT may even
allow for HLA matching, which is currently not done rou-
tinely due to the limited time and may have a favorable
impact on short- and long-term outcomes.As described above, the opportunity to use PSF in the
case of DCD hearts is intriguing. Currently it is per-
ceived that the poor quality of the DCD heart does not
merit the investment of resources required for their re-
covery and the added risk absorbed by the potential re-
cipient. The opportunity to resuscitate organs damaged
by prolonged WIT and to better prevent their deterior-
ation during storage should provide the impetus to pursue
the development of promising preservation strategies such
as PSF. Even if improvements in preservation strategy do
not lead to an immediate increase in the number of trans-
plantable organs, an incremental improvement in this area
should be welcomed. The motivation for this is reflected
in the significant average attrition rate of the heart waitlist
(due to deterioration in health or death) of about 20% per
year (based on data from 2001–2009) (UNOS Data as of
April 30th, 2010). Consequently, seeking better ways to
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should continue to be a primary objective.
To expand the acceptance and utilization of PSF in
organ preservation, the technique must be further deve-
loped. Future work in PSF should involve: 1) continued
optimization of technique and/or operational parameters
(e.g., pO2, pressures, cannulation approach, etc.) so they
are tailored to the tissue/organ-of-interest; 2) explor-
ation of its use in conjunction with other preservation
techniques (such as with HMP); or 3) as a method to
condition organs prior to reperfusion (endischemic condi-
tioning); 4) direct comparison with other well-accepted
preservation techniques; 5) development of portable
PSF systems (such as the electrochemical oxygen con-
centrator); 6) the identification of single or multiple
pharmacologic agents used to prevent or reduce ischemia-
reperfusion injury; and 7) confirmation that ex vivo PSF
should not be considered analogous to in vivo gas em-
bolization, and education of the clinical community re-
garding that embolization should not occur if PSF is
performed properly.
In addition to its application with donor hearts prior
to transplant, PSF may have utility during open cardiac
surgery. As reviewed herein, the early works by Sabiston
and Talbert et al. [14,15], and Camishion et al. [18] have
inspired a reevaluation of the current method of preser-
vation during cardiac standstill [31,43] and may suggest
that PSF could improve outcomes following some or all
cardiac surgery requiring CPB. The duration of cold is-
chemia involved during most coronary arterial bypass or
valve procedures is relatively short (60–90 minutes) and
does not seem to directly cause irreversible cardiac com-
plications. Though supported by our current practice,
this conventional understanding may need challenging.
It could be that improved oxygenation during this rela-
tively short period may reduce the complications that
are believed to be associated with prolonged cross-clamp
times (reduced ventricular compliance, poor inotropy,
dysrhythmia, myocardial infarction, and others), but this
hypothesis would need to be tested rigorously.
Conclusions
As described in this review, oxygen gas delivered by PSF
can be used by the heart during hypothermic preserva-
tion. PSF has shown that it may be capable of extending
the allowable WIT and CIT and may maintain superior
organ quality when compared with SCS. The basis be-
hind the intervention of PSF is to provide an adequate
oxygen supply to an organ during preservation. Data
collected over decades has confirmed that improved
oxygenation is better for maintaining the quality of an
organ and, in some cases, enables the recovery of revers-
ibly damaged tissue. Studies presented in this review
have demonstrated PSF exhibits the capacity to improveor maintain the metabolic quality and function of the
heart following procurement for transplantation. A major
potential benefit to the use of PSF lies in the possibi-
lity to increase the number of suitable heart available
for transplantation.
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